

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the month of: January 2018 (Report No. 1)

Commission file number: 001-35932

**ARCTURUS THERAPEUTICS LTD.**  
(Translation of registrant's name into English)

10628 Science Center Drive, Suite 200  
San Diego, California 92121  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): \_\_\_\_\_

---

---

Effective January 23, 2018, Orli Tori resigned as a member of the board of directors of Arcturus Therapeutics Ltd. (the “Registrant”). Ms. Tori’s resignation was for personal reasons and not due to any disagreement with the Registrant.

This Form 6-K is incorporated by reference into the Registration Statements on Form F-3 (File No. 333- 209960) and Form S-8 (File No. 333-194875, File No. 333-202394, File No. 333-209947, File No. 333-217556 and File No. 333-221830) of the Registrant, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 24, 2018

**Arcturus Therapeutics Ltd.**

By: /s/ Stuart Collinson  
Name: Stuart Collinson  
Title: Executive Chairman

---